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Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumors worldwide. The annual incidence 
ranges from <10 cases per 100,000 persons in North America 
and western Europe to 50–150 cases per 100,000 persons in 
parts of Africa and Asia, where HCC is responsible for a large 
proportion of cancer-related deaths. However, a rise in the 
incidence of and mortality from HCC, most likely reflecting 
the increased prevalence of hepatitis C virus (HCV) infection, 
obesity, and diabetes mellitus, has been observed in most in-
dustrialized countries (1-4).
The major etiologies of HCC are well defined including: 
Chronic viral hepatitis B, C, and D; Toxins and drugs (e.g, al-
cohol, aflatoxins, anabolic steroids); Metabolic liver diseases 
(e.g., hereditary hemochromatosis, alpha-1-antitrypsin defi-
ciency); Diabetes mellitus, obesity in men, nonalcoholic fat-
ty liver disease (NAFLD). Some of the steps in the molecular 
pathogenesis of HCC have been elucidated in recent years. 
Little is known about the incidence and causes of HCC in 
Iran—particularly in the large province of Kerman, in south-
east Iran, which has a population of approximately 2.6 mil-
lion people. 
In  recently  published  article  by  Hepatitis  Monthly,  Dr. 
Sodaif Darvishmoghadam and colleagues, presented a de-
tailed analysis of the epidemiology of HCC in this province 
and compare it with nationwide data from a report by the 
Iranian Cancer Registry Program, published in 2008 (5, 6). 
Between 1999 and 2006, 95 cases of confirmed HCC were 
reported in Kerman, corresponding to a crude annual inci-
dence of 0.522 cases per 100,000 persons. The standardized 
annual incidence was 0.7 per 100,000 persons. Nationwide, 
the crude and standardized annual HCC incidence was 0.199 
and 0.2 per 100,000 persons, respectively. In males, it was 
0.9 and 0.4 in females, indicating an approximately 2-fold 
higher risk for HCC in men compared with females. Further, 
the authors demonstrated that HCC patients in Kerman are 
significanty younger than in Iran in general. The incidence 
of HCC is significantly lower in Iran and its provinces com-
pared with other parts of the world, including Africa, East 
Asia, North America, Western Europe, and the Middle East, 
presumably due to the low incidence of hepatitis B virus 
(HBV) and HCV infection as well as alcoholic liver disease. 
Notably, in Iran there are provinces that experience an ex-
tremely low number of HCC cases annually, such as Arde-
bil, Guilan, and Golestan, and provinces that have a low but 
significantly higher incidence, such as Kerman, Fars, Razavi 
Khorasan, and most notably Tehran, Kerman province show-
ing  the  highest  crude  annual  incidence.  The  reasons  for 
these geographic differences in the mean number of annual 
HCC cases, the crude annual incidence, and the distribution 
of ages in patients with HCC in Iran have not been deter-
mined. Further studies should address these issues to re-
duce the incidence of HCC. In this context, in addition to risk 
factors, preventive compounds, such as coffein (7-9), should 
be considered. Such studies are particulary important for 
provinces in Iran that have a higher incidence of HCC, where 
it remains a devastating malignant disease with very limited 
therapeutic options. 
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  Implication for health policy/practice/research/medical educa-
tion:
The necessity of more attention towards hepatocellular carcinoma 
as one of the causes of mortality in patients with end stage liver fail-
ure should be considered by internists, infectious disease special-
ists, gastroenterologists and general practitioners.
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